SEC Form 4/A · accession 0001214659-26-011110
Alzamend Neuro, Inc. · ALZN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Milton C Ault III
Director
Period of report
Apr 14, 2026
Accepted (ET)
Aug 31, 2026 · 6:00 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001677077
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 14, 2026 | P | 108,388 | $1.0047 | A | 116,648 | I | By Ault Lending, LLC |
| Common StockF2 | Apr 14, 2026 | P | 2,000 | $1.0338 | A | 2,000 | D | |
| Common StockF3 | holding | — | — | — | 11,068 | I | By Ault Life Sciences, Inc. | |
| Common StockF4 | holding | — | — | — | 61 | I | By Ault Life Sciences Fund, LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Milton C. Ault, III, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.
- F2The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $1.0338. The range of purchase prices on the transaction date was $1.00 to $1.05 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
- F3Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.
- F4Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.
Remarks
The original Form 4 filed on April 16, 2026 (the "Original Filing") is amended by this Form 4/A solely to report shares of common stock purchased by the reporting person that were inadvertently omitted from the Original Filing. Other than the correction reflected herein, no changes have been made to the transactions or holdings previously reported in the Original Filing.